Efficacy of VAB (Vonoprazan, Amoxicillin and Bismuth subsalicylate) versus standard triple therapy for Helicobacter pyroli eradication: A randomized controlled trial

Phase 4

• Conditions: Helicobacter pyroli eradication rate by VAB (Vonoprazan, Amoxicillin and Bismuth subsalicylate) regimen; Helicobacter pylori; Bismuth subsalicylate

• Registration Number: TCTR20210928005
• Lead Sponsor: Department of Medicine, Phramongkutklao hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-09-28
• Study Completion: 2023-06-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: nknown
• Sex: All
• Target Recruitment: 160

Inclusion Criteria

Age > 20 years, Postive test of H. pylori infection (Urea breath test, Stool Ag test, EGD with Rapid urease test or Tissue pathology) with agreement

Exclusion Criteria

Active upper gastrointestinal bleeding, eGR < 30 ml/min/1.73m2, drug allergy, pregnancy or lactation, hemodynamic instability, previous treatment of H. pylori infection, HIV infection, Neuroendocrine tumor

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Eradication rate 4 week after treatment each group Helicobacter pylori assessment by Urea breath test or stool Ag test or EGD with rapid urease test

Secondary Outcome Measures

Name	Time	Method
Adverse drug reaction During treatment each group Side effect